COMMUNIQUÉS West-GlobeNewswire

RxSight, Inc. Reports Second Quarter 2024 Financial Results
05/08/2024
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
05/08/2024
–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are [...]
Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance
05/08/2024
Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 [...]
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
05/08/2024
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Singapore’s National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia
05/08/2024
This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic [...]
Oncocyte Announces August Investor Conferences Participation
05/08/2024
IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following [...]
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
05/08/2024
RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
05/08/2024
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in [...]
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
05/08/2024
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Anika to Participate in the Sidoti Virtual Investor Conference
05/08/2024
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the [...]
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
05/08/2024
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
05/08/2024
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation [...]
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
05/08/2024
Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) ; preliminary data expected in 4Q 2024 New SPR720 in-vitro resistance [...]
Akoya Biosciences Reports Second Quarter 2024 Financial Results
05/08/2024
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the second quarter ending June 30, 2024 [...]
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
05/08/2024
Adding Ultimovacs’ cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell carcinoma UV1 continues to [...]
Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
05/08/2024
The six-month efficacy endpoint of overall success showed a statistically significant improvement over standard of care, two-stage exchange arthroplasty DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc [...]
Transparency Notification from Shareholders
05/08/2024
PRESS RELEASE REGULATED INFORMATION 5 August 2024, 06 pm CEST Transparency Notification from Shareholders Ghent, Belgium – 5 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana [...]
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
05/08/2024
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Juillet 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/08/2024
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Pages